Unigene Laboratories Inc had built a robust portfolio of proprietary partnerships in the drug class based on the Companys Peptelligence platform, until it went out of business in 2013 following bankrupcy proceedings. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies. The Companys first product to market, Fortical®, a nasal calcitonin product, received FDA approval in 2005 and was marketed by Upsher-Smith for the treatment of postmenopausal osteoporosis. Pivotal clinical programs included an oral calcitonin licensed to Tarsa Therapeutics, now in Phase 3 testing for the treatment of osteoporosis. Other validating relationships included an oral parathyroid hormone entering Phase 2 in the first quarter of 2011 and licensed to GlaxoSmithKline. In addition, Unigene had a manufacturing license agreement with Novartis, which is completing 3 Phase III studies of oral calcitonin for the treatment of osteoporosis and osteoarthritis. Unigenes technologies have extensive clinical and partner validation.
